• 1
    World Health Organization (2000) Obesity: Preventing and Managing the Global Epidemic. WHO Technical Series Report 894 World Health Organization Geneva, Switzerland.
  • 2
    NHLBI Obesity Initiative Task Force (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res 9(Suppl 2): 51S209S.
  • 3
    Flegal, K. M., Carroll, M. D., Ogden, C. L., Johnson, C. L. (2002) Prevalence and trends in obesity among US adults, 1999–2000. JAMA 288: 17231727.
  • 4
    Bray, G. A. (1988) Obesity: a time bomb to be defused. Lancet 352: 160161.
  • 5
    King, H., Aubert, R. E., Herman, W. H. (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 14141431.
  • 6
    Thomas P. R., eds. (1995) Weighing the Options: Criteria for Evaluating Weight-Management Programs National Academy Press Washington, DC.
  • 7
    Bray, G. A., Blackburn, G. L., Ferguson, J. M., et al. (1999) Sibutramine produces dose-related weight loss. Obes Res 7: 189198.
  • 8
    Sjöström, L., Rissanen, A., Andersen, T., European Multicentre Orlistat Study Groupet al (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 352: 167172.
  • 9
    York, D. A., Singer, L., Thomas, S., Bray, G. A. (2000) Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition 16: 967975.
  • 10
    Richard, D., Picard, F., Lemieux, C., Lalonde, J., Samson, P., Deshaies, Y. (2002) The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 26: 344353.
  • 11
    Reife, R., Pledger, G., Wu, S. C. (2000) Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 41(Suppl 1): S66S71.
  • 12
    Rosenfeld, W. E. (1997) Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin Ther 19: 12941308.
  • 13
    McElroy, S. L., Suppes, T., Keck, P. E., Jr, et al. (2000) Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 47: 10251033.
  • 14
    Shapira, N. A., Goldsmith, T. D., McElroy, S. L. (2000) Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 61: 368372.
  • 15
    World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June, 1964, and amended by the 48th WMA General Assembly, Somerset West, Republic of South Africa, October, 1996.
  • 16
    Dunnett, C. W., Tamhane, A. C. (1991) Step-down multiple tests for comparing treatments with a control in unbalanced one-way layouts. Stat Med 10: 939947.
  • 17
    Kaplan, E. L., Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457481.
  • 18
    Rogawski, M. A., Porter, R. J. (1990) Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 42: 223286.
  • 19
    Macdonald, R. L., McLean, M. J. (1986) Anticonvulsant drugs: mechanisms of action. Adv Neurol 44: 713736.
  • 20
    Munro, J. F., MacCuish, A. C., Wilson, E. M., Duncan, LJP. (1968) Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1: 352354.
  • 21
    Guy-Grand, B., Apfelbaum, M., Crepaldi, G., Gries, A., Lefebvre, P., Turner, P. (1989) International trial of long-term dexfenfluramine in obesity. Lancet 2: 11421145.
  • 22
    Weintraub, M., Sundaresan, P. R., Madan, M., et al. (1992) Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 51: 586594.
  • 23
    Wirth, A., Krause, J. (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 13311339.
  • 24
    Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., European Orlistat Obesity Study Group (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 8: 4961.
  • 25
    Davidson, M. H., Hauptman, J., DiGirolamo, M., et al. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281: 235242.
  • 26
    Hauptman, J., Lucas, C., Boldrin, M. N., Collins, H., Segal, K. R., Orlistat Primary Care Study Group (2000) Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 9: 160167.
  • 27
    Bray, G. A., Greenway, F. L. (1999) Current and potential drugs for treatment of obesity. Endocr Rev 20: 805875.
  • 28
    Goldstein, D. J. (1992) Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16: 397415.
  • 29
    Tuomilehto, J., Lindstrom, J., Eriksson, J. G., Finnish Diabetes Prevention Study Groupet al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 13431350.
  • 30
    The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393403.
  • 31
    Cutler, J. A. (1991) Randomized clinical trials of weight reduction in nonhypertensive persons. Ann Epidemiol 1: 363370.
  • 32
    Dattilo, A. M., Kris-Etherton, P. M. (1992) Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 56: 320328.
  • 33
    O'Connor, H. T., Richman, R. M., Steinbeck, K. S., Caterson, I. D. (1995) Dexfenfluramine treatment of obesity: a double blind trial with post trial follow-up. Int J Obes Relat Metab Disord 19: 181189.
  • 34
    Van Gaal, L. F., Broom, J. I., Enzi, G., Toplak, H., Orlistat Dose-Ranging Study Group (1998) Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 54: 1251332.